Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
DUOCARMYCIN ADCS FOR USE IN THE TREATMENT OF BLADDER CANCER
No-Receipt date
2018-01945 - 08/06/2018
No-Filing date
20180401549 - 08/06/2018
No-Granting date
3096620 - 05/09/2018
No-EPO application date
16160637.1 - 09/01/2015
No-EPO granting date
3069735 - 14/03/2018
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
9/2018 - 09/01/2019
Expiration date
10/01/2035
Kind of title
Validation of European Patent
Legal status
VALID
Priorities
EP1415079110/01/2014/EP
EP1418845010/10/2014/EP
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61P 35/00
A61K 47/50
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1249323
BYONDIS B.V.
MICROWEG 22
6545 CM NIJMEGEN, THE NETHERLANDS
NETHERLANDS
Inventors
Code
Firstname
Surname
2187981
DOKTER, WILLEM
2187982
GOEDINGS, PETER JOHANNES
2187983
VERHEIJDEN, GIJSBERTUS FRANCISCUS MARIA
2187984
BEUSKER, PATRICK HENRY
Representatives
Code
Firstname
Surname
Address
Town
Zip
2937
ATHANASIOS
MASOULAS
SINA 11
ATHINA (ATTIKIS)
10680
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
3079
ATHANASIOS
MASOULAS
SINA 11
ATHINA (ATTIKIS)
10680
GREECE
Owners History
Date
Description
Comments
Data before modification
Data after modification
25/09/2020
Αλλαγή Επωνυμίας Δικαιούχου (7e801)
Α.Π.10063, ΑΡ.ΥΠ.3506249/8-20, ΔΝΥ1410, ΚΩΔ.ΠΛΗΡ.1051
880065 Synthon Biopharmaceuticals B.V. Microweg 22 ΟΛΛΑΝΔΙΑ 6545 CM Nijmegen
1249323 Byondis B.V. Microweg 22 ΟΛΛΑΝΔΙΑ 6545 CM Nijmegen, THE NETHERLANDS
Title Instruments
Payments history
10 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).